

Bernard Fermini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7679265/publications.pdf>

Version: 2024-02-01

33
papers

2,916
citations

304743

22
h-index

454955

30
g-index

38
all docs

38
docs citations

38
times ranked

2137
citing authors

#	ARTICLE	IF	CITATIONS
1	Sustained depolarization-induced outward current in human atrial myocytes. Evidence for a novel delayed rectifier K ⁺ current similar to Kv1.5 cloned channel currents.. Circulation Research, 1993, 73, 1061-1076.	4.5	537
2	The impact of drug-induced QT interval prolongation on drug discovery and development. Nature Reviews Drug Discovery, 2003, 2, 439-447.	46.4	444
3	Identity of a novel delayed rectifier current from human heart with a cloned K ⁺ channel current.. Circulation Research, 1993, 73, 210-216.	4.5	309
4	A New Perspective in the Field of Cardiac Safety Testing through the Comprehensive In Vitro Proarrhythmia Assay Paradigm. Journal of Biomolecular Screening, 2016, 21, 1-11.	2.6	259
5	Rapid and slow components of delayed rectifier current in human atrial myocytes. Cardiovascular Research, 1994, 28, 1540-1546.	3.8	218
6	Delayed rectifier outward current and repolarization in human atrial myocytes.. Circulation Research, 1993, 73, 276-285.	4.5	180
7	Use-Dependent Effects of the Class III Antiarrhythmic Agent NE-10064 (Azimilide) on Cardiac Repolarization. Journal of Cardiovascular Pharmacology, 1995, 26, 259-271.	1.9	116
8	Adrenergic Modulation of Ultrarapid Delayed Rectifier K ⁺ Current in Human Atrial Myocytes. Circulation Research, 1996, 78, 903-915.	4.5	113
9	Î±-Adrenergic Control of Volume-Regulated Cl ⁻ Currents in Rabbit Atrial Myocytes. Circulation Research, 1995, 77, 379-393.	4.5	79
10	Differential effect of HERG blocking agents on cardiac electrical alternans in the guinea pig. European Journal of Pharmacology, 2004, 486, 209-221.	3.5	68
11	Cardiac voltage-gated ion channels in safety pharmacology: Review of the landscape leading to the CiPA initiative. Journal of Pharmacological and Toxicological Methods, 2017, 87, 11-23.	0.7	58
12	Differentiation of Arrhythmia Risk of the Antibacterials Moxifloxacin, Erythromycin, and Telithromycin Based on Analysis of Monophasic Action Potential Duration Alternans and Cardiac Instability. Journal of Pharmacology and Experimental Therapeutics, 2006, 318, 352-359.	2.5	49
13	Clinical Trials in a Dish: A Perspective on the Coming Revolution in Drug Development. SLAS Discovery, 2018, 23, 765-776.	2.7	49
14	Mechanism of Action Potential Prolongation by RP 58866 and Its Active Enantiomer, Terikalant. Circulation, 1996, 94, 2938-2946.	1.6	47
15	Deranged sodium to sudden death. Journal of Physiology, 2015, 593, 1331-1345.	2.9	46
16	Comparative Gene Expression Profiling in Human-Induced Pluripotent Stem Cell-Derived Cardiocytes and Human and Cynomolgus Heart Tissue. Toxicological Sciences, 2013, 131, 292-301.	3.1	41
17	Measuring kinetics and potency of hERG block for CiPA. Journal of Pharmacological and Toxicological Methods, 2017, 87, 99-107.	0.7	41
18	Amiodarone: Pharmacology, Clinical Actions, and Relationships Between Them. Journal of Cardiovascular Electrophysiology, 1992, 3, 266-280.	1.7	38

#	ARTICLE	IF	CITATIONS
19	Evaluation of the Rubidium Efflux Assay for Preclinical Identification of hERG Blockade. Assay and Drug Development Technologies, 2006, 4, 73-82.	1.2	37
20	Human Cardiac Ventricularâ€Like Organoid Chambers and Tissue Strips From Pluripotent Stem Cells as a Twoâ€Tiered Assay for Inotropic Responses. Clinical Pharmacology and Therapeutics, 2019, 106, 402-414.	4.7	36
21	Proarrhythmia liability assessment and the comprehensive in vitro Proarrhythmia Assay (CiPA): An industry survey on current practice. Journal of Pharmacological and Toxicological Methods, 2017, 86, 34-43.	0.7	32
22	Pharmacokineticâ€pharmacodynamic modelling of the effect of Moxifloxacin on QTc prolongation in telemetered cynomolgus monkeys. Journal of Pharmacological and Toxicological Methods, 2011, 63, 304-313.	0.7	30
23	Use of automated patch clamp in cardiac safety assessment: past, present and future perspectives. Journal of Pharmacological and Toxicological Methods, 2021, 110, 107072.	0.7	20
24	Challenges in designing and executing clinical trials in a dish studies. Journal of Pharmacological and Toxicological Methods, 2018, 94, 73-82.	0.7	15
25	Computational cardiology and risk stratification for sudden cardiac death: one of the grand challenges for cardiology in the 21st century. Journal of Physiology, 2016, 594, 6893-6908.	2.9	14
26	Sialic acid and the surface charge associated with hyperpolarization-activated, inward rectifying channels. Journal of Membrane Biology, 1990, 114, 61-69.	2.1	10
27	L-type calcium channel antagonism â€ Translation from in vitro to in vivo. Journal of Pharmacological and Toxicological Methods, 2017, 84, 86-92.	0.7	10
28	Recent Advances in Ion Channel Screening Technologies. Topics in Medicinal Chemistry, 2008, , 1-25.	0.8	8
29	Pre-Clinical Assessment of Drug-Induced QT Interval Prolongation. Current Issues and Impact on Drug Discovery. Annual Reports in Medicinal Chemistry, 2004, 39, 323-334.	0.9	7
30	On the perspective of an aging population and its potential impact on drug attrition and pre-clinical cardiovascular safety assessment. Journal of Pharmacological and Toxicological Methods, 2022, 117, 107184.	0.7	5
31	Species comparison of L-type Ca ²⁺ currents in cardiac myocytes isolated from rat, rabbit, and non-human primate. Journal of Pharmacological and Toxicological Methods, 2011, 64, e5.	0.7	0
32	The use of alternate QRS measurement methods to improve detection of propafenone-induced QRS prolongation. Journal of Pharmacological and Toxicological Methods, 2011, 64, e39.	0.7	0
33	Use of an in vitro contractility assay to explore cardiac contractility changes observed in an in vivo cardiovascular study. Journal of Pharmacological and Toxicological Methods, 2013, 68, e21.	0.7	0